Literature DB >> 23201582

Cellular immunity in ASFV responses.

Haru-Hisa Takamatsu1, Michael S Denyer, Anna Lacasta, Catrina M A Stirling, Jordi M Argilaguet, Christopher L Netherton, Chris A L Oura, Carlos Martins, Fernando Rodríguez.   

Abstract

African swine fever virus (ASFV) infection usually results in an acute haemorrhagic disease with a mortality rate approaching 100% in domestic pigs. However, pigs can survive infection with less-virulent isolates of ASFV and may become chronically infected. Surviving animals are resistant to challenge with homologous or, in some cases, closely related isolates of the virus indicating that pigs can develop protective immunity against ASFV. During asymptomatic, non-virulent ASFV infections natural killer cell activity increases in pigs, suggesting this cell type plays a role in ASFV immunity. Furthermore, depletion of CD8(+) lymphocytes from ASFV immune pigs demolishes protective immunity against related virulent viruses. This suggests that ASFV specific antibody alone is not sufficient for protection against ASFV infection and that there is an important role for the CD8(+) lymphocyte subset in ASFV protective immunity. These results were supported by DNA immunization studies, demonstrating a correlation between the protection afforded against lethal challenge and the detection of a large number of vaccine-induced antigen-specific CD8(+) T-cells. Peripheral blood mononuclear cells (PBMCs) from ASF immune pigs protected from clinical disease show higher proportions of ASFV specific CD4(+)CD8(high+) double positive cytotoxic T cells than PBMCs from ASF immune but clinically diseased pig. The frequency of ASFV specific IFNγ producing T cells induced by immunization correlates to the degree of protection from ASFV challenge, and this may prove to be a useful indicator of any potential cross-protection against heterologous ASFV isolates.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23201582     DOI: 10.1016/j.virusres.2012.11.009

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  49 in total

1.  Serum Neutralizing and Enhancing Effects on African Swine Fever Virus Infectivity in Adherent Pig PBMC.

Authors:  Jessica A Canter; Theresa Aponte; Elizabeth Ramirez-Medina; Sarah Pruitt; Douglas P Gladue; Manuel V Borca; James J Zhu
Journal:  Viruses       Date:  2022-06-09       Impact factor: 5.818

2.  Transcriptome profiling in swine macrophages infected with African swine fever virus at single-cell resolution.

Authors:  Yuxuan Zheng; Su Li; Shi-Hua Li; Shaoxiong Yu; Qihui Wang; Kehui Zhang; Liang Qu; Yuan Sun; Yuhai Bi; Fuchou Tang; Hua-Ji Qiu; George F Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-04       Impact factor: 12.779

3.  Induction of Robust Immune Responses in Swine by Using a Cocktail of Adenovirus-Vectored African Swine Fever Virus Antigens.

Authors:  Shehnaz Lokhandwala; Suryakant D Waghela; Jocelyn Bray; Cameron L Martin; Neha Sangewar; Chloe Charendoff; Rashmi Shetti; Clay Ashley; Chang-Hsin Chen; Luc R Berghman; Duncan Mwangi; Paul J Dominowski; Dennis L Foss; Sharath Rai; Shaunak Vora; Lindsay Gabbert; Thomas G Burrage; David Brake; John Neilan; Waithaka Mwangi
Journal:  Clin Vaccine Immunol       Date:  2016-11-04

4.  Expression library immunization can confer protection against lethal challenge with African swine fever virus.

Authors:  Anna Lacasta; María Ballester; Paula L Monteagudo; Javier M Rodríguez; María L Salas; Francesc Accensi; Sonia Pina-Pedrero; Albert Bensaid; Jordi Argilaguet; Sergio López-Soria; Evelyne Hutet; Marie Frédérique Le Potier; Fernando Rodríguez
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

5.  Mutations in a Highly Conserved Motif of nsp1β Protein Attenuate the Innate Immune Suppression Function of Porcine Reproductive and Respiratory Syndrome Virus.

Authors:  Yanhua Li; Duan-Liang Shyu; Pengcheng Shang; Jianfa Bai; Kang Ouyang; Santosh Dhakal; Jagadish Hiremath; Basavaraj Binjawadagi; Gourapura J Renukaradhya; Ying Fang
Journal:  J Virol       Date:  2016-01-20       Impact factor: 5.103

6.  BA71ΔCD2: a New Recombinant Live Attenuated African Swine Fever Virus with Cross-Protective Capabilities.

Authors:  Paula L Monteagudo; Anna Lacasta; Elisabeth López; Laia Bosch; Javier Collado; Sonia Pina-Pedrero; Florencia Correa-Fiz; Francesc Accensi; María Jesús Navas; Enric Vidal; María J Bustos; Javier M Rodríguez; Andreas Gallei; Veljko Nikolin; María L Salas; Fernando Rodríguez
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

7.  The Role of Interleukine-10 and Interferon-γ as Potential Markers of the Evolution of African Swine Fever Virus Infection in Wild Boar.

Authors:  Sandra Barroso-Arévalo; Jose A Barasona; Estefanía Cadenas-Fernández; Jose M Sánchez-Vizcaíno
Journal:  Pathogens       Date:  2021-06-15

8.  Live attenuated African swine fever viruses as ideal tools to dissect the mechanisms involved in viral pathogenesis and immune protection.

Authors:  Anna Lacasta; Paula L Monteagudo; Ángeles Jiménez-Marín; Francesc Accensi; María Ballester; Jordi Argilaguet; Iván Galindo-Cardiel; Joaquim Segalés; María L Salas; Javier Domínguez; Ángela Moreno; Juan J Garrido; Fernando Rodríguez
Journal:  Vet Res       Date:  2015-11-20       Impact factor: 3.683

Review 9.  Approaches and Perspectives for Development of African Swine Fever Virus Vaccines.

Authors:  Marisa Arias; Ana de la Torre; Linda Dixon; Carmina Gallardo; Ferran Jori; Alberto Laddomada; Carlos Martins; R Michael Parkhouse; Yolanda Revilla; Fernando And Jose-Manuel Rodriguez
Journal:  Vaccines (Basel)       Date:  2017-10-07

10.  Deletion of the African Swine Fever Virus Gene DP148R Does Not Reduce Virus Replication in Culture but Reduces Virus Virulence in Pigs and Induces High Levels of Protection against Challenge.

Authors:  Ana L Reis; Lynnette C Goatley; Tamara Jabbar; Pedro J Sanchez-Cordon; Christopher L Netherton; David A G Chapman; Linda K Dixon
Journal:  J Virol       Date:  2017-11-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.